How Many Evoke Pharma, Inc. (NASDAQ:EVOK)’s Analysts Are Bearish?

January 13, 2018 - By Migdalia James

 How Many Evoke Pharma, Inc. (NASDAQ:EVOK)'s Analysts Are Bearish?
Investors sentiment increased to 4.5 in Q3 2017. Its up 3.00, from 1.5 in 2017Q2. It is positive, as 2 investors sold Evoke Pharma, Inc. shares while 0 reduced holdings. 4 funds opened positions while 5 raised stakes. 4.20 million shares or 123.21% more from 1.88 million shares in 2017Q2 were reported.
Moreover, California Employees Retirement has 0% invested in Evoke Pharma, Inc. (NASDAQ:EVOK). Vanguard Group holds 0% in Evoke Pharma, Inc. (NASDAQ:EVOK) or 523,650 shares. Sphera Funds has invested 0.27% in Evoke Pharma, Inc. (NASDAQ:EVOK). Citigroup, New York-based fund reported 500 shares. Blackrock holds 62,369 shares or 0% of its portfolio. Wells Fargo & Company Mn holds 0% in Evoke Pharma, Inc. (NASDAQ:EVOK) or 8,057 shares. Virtu Fincl Limited Liability Com accumulated 39,489 shares. Commonwealth Equity Serv, Massachusetts-based fund reported 30,062 shares. Geode Mngmt Ltd owns 23,048 shares. Fin Advisers Limited Liability Corp owns 15,566 shares or 0% of their US portfolio. National Bank Of Mellon Corporation invested in 24,908 shares. Two Sigma Securities Ltd Liability Corporation accumulated 11,137 shares. Bank Of America Corporation De reported 10,000 shares. Moreover, Millennium Llc has 0% invested in Evoke Pharma, Inc. (NASDAQ:EVOK) for 54,853 shares. Pnc Finance Services Gru reported 0% stake.

Evoke Pharma, Inc. (NASDAQ:EVOK) Ratings Coverage

Among 9 analysts covering Evoke Pharma (NASDAQ:EVOK), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Evoke Pharma had 19 analyst reports since August 20, 2015 according to SRatingsIntel. The stock has “Hold” rating by Noble Financial on Tuesday, July 19. The firm has “Buy” rating given on Monday, March 14 by Ascendiant Capital. On Monday, July 18 the stock rating was downgraded by Rodman & Renshaw to “Neutral”. FBR Capital maintained Evoke Pharma, Inc. (NASDAQ:EVOK) rating on Wednesday, November 15. FBR Capital has “Buy” rating and $10.0 target. H.C. Wainwright initiated it with “Buy” rating and $27 target in Thursday, October 1 report. Northland Capital initiated Evoke Pharma, Inc. (NASDAQ:EVOK) on Wednesday, March 16 with “Outperform” rating. Rodman & Renshaw maintained Evoke Pharma, Inc. (NASDAQ:EVOK) on Friday, December 23 with “Neutral” rating. The firm earned “Buy” rating on Tuesday, October 24 by H.C. Wainwright. The firm earned “Buy” rating on Tuesday, August 15 by H.C. Wainwright. The firm has “Buy” rating by Rodman & Renshaw given on Friday, October 2. Below is a list of Evoke Pharma, Inc. (NASDAQ:EVOK) latest ratings and price target changes.

29/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0 Maintain
15/11/2017 Broker: FBR Capital Rating: Buy New Target: $10.0 Maintain
24/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0 Maintain
18/10/2017 Broker: FBR Capital Rating: Buy New Target: $10.0
06/10/2017 Broker: Seaport Global Rating: Buy New Target: $10 Initiates Coverage On
18/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0 Maintain
15/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.0000 Maintain

The stock decreased 1.60% or $0.042 during the last trading session, reaching $2.578. About 72,406 shares traded. Evoke Pharma, Inc. (NASDAQ:EVOK) has declined 51.99% since January 13, 2017 and is downtrending. It has underperformed by 68.69% the S&P500.

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. The company has market cap of $39.74 million. It is developing Gimoti, a metoclopramide nasal spray, which completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. It currently has negative earnings.

More notable recent Evoke Pharma, Inc. (NASDAQ:EVOK) news were published by: Seekingalpha.com which released: “Evoke Pharma’s (EVOK) CEO David Gonyer on Q1 2017 Results – Earnings Call …” on May 16, 2017, also Globenewswire.com with their article: “Evoke Pharma Announces Positive Topline Results from Comparative Exposure …” published on October 23, 2017, Seekingalpha.com published: “Evoke Pharma: Hop On And Ride The Elevator Higher” on July 31, 2016. More interesting news about Evoke Pharma, Inc. (NASDAQ:EVOK) were released by: Marketwatch.com and their article: “Evoke Pharma’s stock soars after FDA exempts Gimoti from HF Validation” published on February 15, 2017 as well as Globenewswire.com‘s news article titled: “Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma’s …” with publication date: April 04, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.